Liquidia Corp

LQDA

Market cap $3.3B

Does Liquidia Corporation (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The biotech posted preliminary sales results for Yutrepia. This is its latest commercialized product, approved by the FDA in May 2025.

Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and product differentiation in PAH and PH-ILD. LQDA's Yutrepia demonstrates superior tolerability, higher achievable dosing, and rapid titration versus Tyvaso, driving robust commercial uptake and market share gains. Key binary risk centers on the imminent IP litigation outcome versus United Therapeutics; multiple scenarios could impact valuation, but commercial momentum is strong.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA). But which of these two stocks presents investors with the better value opportunity right now?

Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.

The consensus price target hints at a 51.2% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Liquidia Corporation ( LQDA ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM EST Company Participants Roger Jeffs - CEO & Director Michael Kaseta - COO & CFO Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Hi, everyone, thanks so much for attending the Liquidia fireside chat. Day 2 of the conference, the weather in London is getting a little chilly, but it's good for staying awake.

California-based TCG Crossover Management added 1.7 million shares of Liquidia for an estimated $38.9 million in the third quarter. The position represented 1.9% of reported assets at quarter-end.

The consensus price target hints at a 62.3% upside potential for Liquidia Corporation (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.